About EngMab
EngMab is a Healthcare company based in Schwyz (Switzerland) founded in 2013, and was acquired by Celgene in October 2016. T-cell bispecific antibodies are developed for cancer treatment. Its focus areas include Life Sciences, Immunotherapy, Antibody and Disease-Targeting.
Company details
EngMab was founded in 2013 in Schwyz, Switzerland, within the biotechnology sector. T-cell bispecific antibodies (TCBs) are developed for cancer therapy, with a pipeline that includes a TCB targeting high unmet needs in haematological malignancies and another addressing tumour antigens on both haematological and solid tumours. Acquisition by Celgene took place in October 2016.
- Headquarters Schwyz, Switzerland
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website engmab.com
- Acquired by Celgene (Oct 2016)
Investors in EngMab
EngMab has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Celgene.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Therapies for cancer and inflammatory diseases are developed. | 1986 | celgene.com | Summit, United States |
Investor details for EngMab
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of EngMab
2 dated milestones of EngMab across 3 years, from founding to its latest funding, stage changes and deals.
- Founded EngMab is founded.
- Exit Acquired by Celgene.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about EngMab
EngMab was founded in 2013.
EngMab is headquartered in Schwyz, Switzerland. It is registered at Schwyz, Schwyz, Switzerland.
EngMab was founded in 2013 in Schwyz, Switzerland, within the biotechnology sector. T-cell bispecific antibodies (TCBs) are developed for cancer therapy, with a pipeline that includes a TCB targeting high unmet needs in haematological malignancies and another addressing tumour antigens on both haematological and solid tumours. Acquisition by Celgene took place in October 2016.
EngMab has 1 investor. Key investors include Celgene.
Yes. EngMab was acquired by Celgene in October 2016.